{
    "root": "3415dbb0-48df-05e5-e063-6294a90a7516",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Citalopram",
    "value": "20250501",
    "ingredients": [
        {
            "name": "CITALOPRAM HYDROBROMIDE",
            "code": "I1E9D14F36"
        }
    ],
    "indications": "Citalopram tablets are indicated for the treatment of major depressive disorder (MDD) in adults\n \n  [see Clinical Studies (\n  \n   14)]\n \n  .",
    "contraindications": "• Administer once daily with or without food ( 2 ) . • Initial dosage is 20 mg once daily; after one week may increase to maximum dosage of 40 mg once daily ( 2.1 ) . • Patients greater than 60 years of age, patients with hepatic impairment, and CYP2C19 poor metabolizers: maximum recommended dosage is 20 mg once daily ( 2.2 ) . • When discontinuing citalopram tablets, reduce dosage gradually ( 2.4 , 5.6 ) .",
    "warningsAndPrecautions": "Citalopram Tablets, USP contain citalopram hydrobromide USP, equivalent to 20 mg citalopram base.\n                  Citalopram Tablets, USP 20 mg, Tan coloured, oval shaped, biconvex film coated tablets with ‘2│0’ debossed (‘2’ on left side and ‘0’ on right side of the break line) on one side and ‘1010’ on the other side.\n                  \n                  NDC: 70518-4335-00\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Citalopram tablets are contraindicated in patients: \n    • taking, or within 14 days of stopping, MAOIs (including MAOIs such as linezolid or intravenous methylene blue) because of an increased risk of serotonin syndrome\n \n  [see Warnings and Precautions (\n  \n   5.3), Drug Interactions (\n  \n   7)]\n \n  . \n    • taking pimozide because of risk of QT prolongation\n \n  [see Drug Interactions (\n  \n   7)]\n \n  . \n    • with known hypersensitivity to citalopram or any of the inactive ingredients in citalopram tablets. Reactions have included angioedema and anaphylaxis\n \n  [see Adverse Reactions (\n  \n   6.2)]\n \n  ."
}